Eckert & Ziegler: Sales Growth and Jump in Income in First Quarter
Sales in the Isotope Products segment saw a currency-related rise of 2 % in the first quarter of 2017 compared with the prior year. However, sales were supported in the prior year by a one-time demand peak in the energy sector. The absence of this non-recurring effect in the first quarter of 2017 made the continued stable sales and financial performance all the more pleasing.
By contrast, sales in the Radiation Therapy segment declined slightly by € 0.5 million or 6 % to € 6.0 million. Temporary supply difficulties of radioactive prostate implants at the beginning of the year, caused by raw material bottlenecks, were made up for during the quarter, with the result that sales are in fact currently higher than planned.
The strong growth is continuing in the Radiopharma segment. Compared with the prior year’s period, sales increased € 1.6 million or 17 % to € 11.3 million. Significant sales growth was seen particularly in the U.S.
Cash flow from operating activities increased € 4.0 million or 513 % to € 4.7 million. The € 1.2 million higher profit for the period is crucial.
In 2017, earnings are expected to increase and could exceed € 2.00 per share, assuming that exchange rates remain stable and excluding acquisitions and the sale of divisions. Sales of just under € 150 million are expected.
The complete financial statements can be viewed here: http://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz117e.pdf
Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with approximately 610 employees, is one the world's largest providers of isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.